Brought to you by 
Forest gets US, Canadian rights to Fabre's antidepressant
27 Oct 2020
Executive Summary
French pharmaco Pierre Fabre Medicament has licensed Forest Laboratories rights to develop and sell its Phase II antidepressant F2695 in the US and Canada.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forest gets US, Canadian rights to Fabre's antidepressant
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice